SG11201507420UA - Interleukin-2 muteins for the expansion of t-regulatory cells - Google Patents

Interleukin-2 muteins for the expansion of t-regulatory cells

Info

Publication number
SG11201507420UA
SG11201507420UA SG11201507420UA SG11201507420UA SG11201507420UA SG 11201507420U A SG11201507420U A SG 11201507420UA SG 11201507420U A SG11201507420U A SG 11201507420UA SG 11201507420U A SG11201507420U A SG 11201507420UA SG 11201507420U A SG11201507420U A SG 11201507420UA
Authority
SG
Singapore
Prior art keywords
muteins
interleukin
expansion
regulatory cells
regulatory
Prior art date
Application number
SG11201507420UA
Inventor
Marc A Gavin
Gunasekaran Kannan
Li Li
Joshua T Pearson
Margaret Karow
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201507420UA publication Critical patent/SG11201507420UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
SG11201507420UA 2013-03-14 2014-03-14 Interleukin-2 muteins for the expansion of t-regulatory cells SG11201507420UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14
PCT/US2014/029111 WO2014153111A2 (en) 2013-03-14 2014-03-14 Interleukin-2 muteins for the expansion of t-regulatory cells

Publications (1)

Publication Number Publication Date
SG11201507420UA true SG11201507420UA (en) 2015-10-29

Family

ID=50680166

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507574VA SG11201507574VA (en) 2013-03-14 2014-03-14 AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES
SG11201507420UA SG11201507420UA (en) 2013-03-14 2014-03-14 Interleukin-2 muteins for the expansion of t-regulatory cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201507574VA SG11201507574VA (en) 2013-03-14 2014-03-14 AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES

Country Status (40)

Country Link
US (7) US9580486B2 (en)
EP (2) EP2970441B1 (en)
JP (5) JP6480409B2 (en)
KR (4) KR102219124B1 (en)
CN (2) CN105143253B (en)
AP (1) AP2015008737A0 (en)
AR (1) AR095541A1 (en)
AU (2) AU2014236316B2 (en)
BR (1) BR112015022440B1 (en)
CA (3) CA2905141A1 (en)
CL (2) CL2015002686A1 (en)
CR (2) CR20200004A (en)
CY (2) CY1121767T1 (en)
DK (2) DK2970441T3 (en)
EA (2) EA034326B1 (en)
ES (2) ES2737598T3 (en)
HK (1) HK1220695A1 (en)
HR (2) HRP20190970T1 (en)
HU (2) HUE044321T2 (en)
IL (2) IL241349B (en)
JO (1) JO3796B1 (en)
LT (2) LT2970441T (en)
MA (2) MA38477B1 (en)
ME (2) ME03437B (en)
MX (2) MX2015012890A (en)
MY (1) MY172991A (en)
NZ (1) NZ751148A (en)
PE (1) PE20151763A1 (en)
PH (1) PH12015502051A1 (en)
PL (2) PL2970423T3 (en)
PT (2) PT2970441T (en)
RS (2) RS58791B1 (en)
SG (2) SG11201507574VA (en)
SI (2) SI2970423T1 (en)
TN (1) TN2015000416A1 (en)
TR (2) TR201908362T4 (en)
TW (3) TWI687435B (en)
UA (1) UA119140C2 (en)
UY (1) UY35454A (en)
WO (2) WO2014153111A2 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2904014A4 (en) * 2012-10-04 2016-09-28 Novelmed Therapeutics Inc Alternative pathway specific antibodies for treating hemolytic diseases
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
UA118843C2 (en) 2013-03-15 2019-03-25 Дженентек, Інк. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
TWI636064B (en) 2013-03-15 2018-09-21 安美基公司 Human pac1 antibodies
CA2931114A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
CA2954847A1 (en) 2014-07-21 2016-01-28 Jeffrey Greve Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3180020B1 (en) 2014-08-11 2018-12-26 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US10934362B2 (en) 2014-09-15 2021-03-02 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
HUE055460T2 (en) 2014-12-15 2021-11-29 Univ Washington Compositions and methods for targeted cytokine delivery
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CR20170510A (en) * 2015-04-10 2018-02-26 Amgen Inc INTERUQUINE MUTEINS 2 FOR THE EXPANSION OF REGULATORY T-CELLS
CA2982362A1 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
CR20180365A (en) 2015-12-16 2018-09-28 Amgen Inc PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EA039859B1 (en) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
MX2018009386A (en) * 2016-02-03 2018-11-09 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
KR20180103084A (en) * 2016-02-03 2018-09-18 암젠 리서치 (뮌헨) 게엠베하 BCMA and CD3 bispecific T cell engrafting antibody constructs
JP7220458B2 (en) 2016-02-05 2023-02-10 ワシントン・ユニバーシティ Compositions and methods for targeted cytokine delivery
CN107287273B (en) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 Application of peripheral blood NK (natural killer) cells expressing Tim-3 in preparation of natural abortion biomarker
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3028829A1 (en) 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (en) * 2016-09-02 2018-12-13 고려대학교 산학협력단 Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
US11384336B2 (en) 2016-12-07 2022-07-12 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells
BR112019018915A2 (en) 2017-03-15 2020-04-14 Pandion Therapeutics Inc targeted immunotolerance
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
MX2019013517A (en) * 2017-05-24 2020-08-17 Pandion Operations Inc Targeted immunotolerance.
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
JP2020537506A (en) 2017-10-04 2020-12-24 アムジエン・インコーポレーテツド Transthyretin immunoglobulin fusion
JP7250790B2 (en) * 2017-12-06 2023-04-03 パンディオン・オペレーションズ・インコーポレイテッド IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN111655718A (en) 2017-12-19 2020-09-11 Xencor股份有限公司 Engineered IL-2 FC fusion proteins
CN111868079A (en) 2017-12-27 2020-10-30 协和麒麟株式会社 IL-2 variants
UY38050A (en) 2018-01-12 2019-07-31 Amgen Inc PAC1 ANTIBODIES AND THEIR USES CROSSED REFERENCE TO RELATED APPLICATIONS
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
CN112154153A (en) 2018-03-28 2020-12-29 百时美施贵宝公司 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2019235895A1 (en) 2018-06-07 2019-12-12 한국생명공학연구원 Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112654633A (en) 2018-06-22 2021-04-13 科优基因公司 Cytokine-based bioactivatable agents and methods of use thereof
JOP20200343A1 (en) 2018-07-02 2020-12-31 Xencor Inc Anti-steap1 antigen-binding protein
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
AU2019370339A1 (en) * 2018-11-01 2021-06-10 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
EP3920899A2 (en) 2019-02-08 2021-12-15 The UAB Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
WO2020168059A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
CN113661175A (en) 2019-02-15 2021-11-16 整体分子公司 Antibodies comprising a common light chain and uses thereof
EP3946424A1 (en) 2019-03-29 2022-02-09 Institut Curie Interleukin-2 variants with modified biological activity
CN111944036A (en) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 Mutant protein for proliferating immune cells
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
AU2020289587A1 (en) 2019-06-07 2021-12-23 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
WO2021007150A1 (en) 2019-07-08 2021-01-14 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
JP2022541657A (en) * 2019-07-26 2022-09-26 ビステラ， インコーポレイテッド Interleukin-2 agonists and uses thereof
US20220289807A1 (en) * 2019-08-13 2022-09-15 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
KR20220061967A (en) 2019-09-13 2022-05-13 쿄와 기린 가부시키가이샤 DcR3 variant
BR112022009521A2 (en) * 2019-11-20 2022-08-16 Gi Cell Inc COMPOSITION OF MEDIUM FOR T-CELL CULTURE AND METHOD FOR T-CELL CULTURE USING THE SAME
WO2021108389A1 (en) * 2019-11-29 2021-06-03 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
IL293628A (en) 2019-12-12 2022-08-01 Iltoo Pharma Interleukin 2 chimeric constructs
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 /tnf receptor agonist for use in therapy
CN115023444A (en) 2019-12-20 2022-09-06 再生元制药公司 Novel IL2 agonists and methods of use thereof
JP7303391B2 (en) 2020-01-14 2023-07-04 シンセカイン インコーポレイテッド Biased IL2 muteins, methods, and compositions
EP4132965A2 (en) * 2020-04-06 2023-02-15 Lung Biotechnology PBC Modular synthetic receptors and methods of use
CN116323647A (en) 2020-05-13 2023-06-23 博纳姆治疗公司 Compositions of protein complexes and methods of use thereof
WO2021247812A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (en) * 2020-08-31 2021-10-08 南方医科大学 Chimeric T cell growth factor and application thereof
CA3195260A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN116783217A (en) 2020-12-03 2023-09-19 安进公司 Immunoglobulin constructs with multiple binding domains
CA3203977A1 (en) * 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202304994A (en) 2021-04-02 2023-02-01 美商泰尼歐生物公司 Agonistic anti-il-2r antibodies and methods of use
IL308733A (en) 2021-05-27 2024-01-01 Sanofi Sa Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
WO2023015298A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
WO2023057588A1 (en) 2021-10-06 2023-04-13 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2023061005A1 (en) * 2021-10-14 2023-04-20 徕特康(苏州)生物制药有限公司 Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
TW202323281A (en) 2021-10-14 2023-06-16 美商泰尼歐生物公司 Mesothelin binding proteins and uses thereof
TW202333772A (en) * 2021-12-01 2023-09-01 美商威特拉公司 Methods of using interleukin-2 agents
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023164476A2 (en) * 2022-02-22 2023-08-31 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007054A1 (en) 1987-03-18 1988-09-22 Research Corporation Limited Complement-binding peptide
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (en) 1996-08-14 1998-10-23 Essilor Int METHOD FOR INCORPORATING ADDITIVES INTO AN OPHTHALMIC ARTICLE USING A SUPERCRITICAL FLUID
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
CA2343080A1 (en) 1998-09-29 2000-04-06 Pioneer Hi-Bred International, Inc. Mar/sar elements flanking rsyn7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (en) 2000-07-29 2003-12-06 한국산업기술평가원 Expression vector using for animal cell
BR0116024A (en) * 2000-12-07 2005-12-13 Lilly Co Eli Heterologous Fusion Protein and Use thereof
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
SG141239A1 (en) 2001-01-26 2008-04-28 Selexis Sa Matrix attachment regions and methods for use thereof
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EA008831B1 (en) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Glp-1 analog fusion proteins
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
WO2005091956A2 (en) 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
CN1930300A (en) * 2004-03-05 2007-03-14 希龙公司 In vitro test system for predicting patient tolerability of therapeutic agents
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
AU2006244497B2 (en) * 2005-05-06 2011-09-22 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
JP2008543839A (en) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド Self-buffering protein formulation
CA2614766A1 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods of treating autoimmune disease using humanized anti-cd16a antibodies
WO2008112325A2 (en) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
AU2010206681A1 (en) * 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
WO2011063348A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
TW201130511A (en) * 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
CN103443125B (en) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 Low-affinity blood-brain barrier receptor antibody and application thereof
EP3971206A1 (en) * 2011-02-10 2022-03-23 Roche Glycart AG Mutant interleukin-2 polypeptides
WO2012125850A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Fc variants
EA201892619A1 (en) * 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2812355A4 (en) 2012-02-06 2016-03-02 Hoffmann La Roche Compositions and methods for using csf1r inhibitors
EP2852618A2 (en) 2012-05-21 2015-04-01 F. Hoffmann-La Roche AG Methods for improving safety of blood-brain barrier transport
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
UA118843C2 (en) * 2013-03-15 2019-03-25 Дженентек, Інк. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
US10093711B2 (en) 2018-10-09
US20180237489A1 (en) 2018-08-23
KR20220101009A (en) 2022-07-18
JP6450365B2 (en) 2019-01-09
HRP20191075T1 (en) 2019-09-20
US9932380B2 (en) 2018-04-03
EP2970423B1 (en) 2019-04-24
NZ751148A (en) 2021-05-28
US20140286898A1 (en) 2014-09-25
AP2015008737A0 (en) 2015-09-30
PT2970423T (en) 2019-07-23
CY1121823T1 (en) 2020-07-31
EA032863B1 (en) 2019-07-31
HUE044321T2 (en) 2019-10-28
CR20150557A (en) 2015-11-10
DK2970423T3 (en) 2019-07-08
TWI784288B (en) 2022-11-21
US10562950B2 (en) 2020-02-18
US20210094997A1 (en) 2021-04-01
AU2014236316A1 (en) 2015-10-08
WO2014153063A1 (en) 2014-09-25
ME03482B (en) 2020-01-20
CA2905141A1 (en) 2014-09-25
RS58854B1 (en) 2019-07-31
KR20150127185A (en) 2015-11-16
KR102418771B1 (en) 2022-07-08
MY172991A (en) 2019-12-17
MX2015012912A (en) 2015-12-03
US20140343252A1 (en) 2014-11-20
BR112015022440A2 (en) 2017-10-24
KR20230157526A (en) 2023-11-16
TR201910802T4 (en) 2019-08-21
PE20151763A1 (en) 2015-12-10
PH12015502051B1 (en) 2016-01-18
CN105358570B (en) 2019-11-12
TW201522366A (en) 2015-06-16
JP2016518823A (en) 2016-06-30
US10829535B2 (en) 2020-11-10
IL241349B (en) 2018-08-30
WO2014153111A2 (en) 2014-09-25
CA3149348A1 (en) 2014-09-25
JP2016514161A (en) 2016-05-19
MA38477B1 (en) 2019-05-31
EP2970441A1 (en) 2016-01-20
AR095541A1 (en) 2015-10-21
CA2906708C (en) 2022-05-03
EA201591731A1 (en) 2016-04-29
JP7227951B2 (en) 2023-02-22
CN105143253A (en) 2015-12-09
JP2019058182A (en) 2019-04-18
AU2014236281A1 (en) 2015-09-24
IL241622B (en) 2020-09-30
LT2970441T (en) 2019-06-10
UY35454A (en) 2014-09-30
CL2015002669A1 (en) 2016-09-09
US20180319859A1 (en) 2018-11-08
AU2014236316A9 (en) 2018-11-08
HK1220695A1 (en) 2017-05-12
JP2023053148A (en) 2023-04-12
RS58791B1 (en) 2019-07-31
EP2970423A2 (en) 2016-01-20
JP6480409B2 (en) 2019-03-13
CL2015002686A1 (en) 2016-04-15
EP2970441A4 (en) 2016-11-23
ES2737598T3 (en) 2020-01-15
TW202005979A (en) 2020-02-01
CY1121767T1 (en) 2020-07-31
EA201591766A1 (en) 2016-02-29
MX366854B (en) 2019-07-26
HRP20190970T1 (en) 2019-07-26
IL241349A0 (en) 2015-11-30
TWI687435B (en) 2020-03-11
SI2970423T1 (en) 2019-08-30
CA2906708A1 (en) 2014-09-25
JO3796B1 (en) 2021-01-31
TR201908362T4 (en) 2019-06-21
PL2970441T3 (en) 2019-09-30
PL2970423T3 (en) 2019-10-31
LT2970423T (en) 2019-05-27
AU2014236316B2 (en) 2018-11-01
ES2720225T3 (en) 2019-07-18
WO2014153111A3 (en) 2014-11-13
US9546203B2 (en) 2017-01-17
US20170137485A1 (en) 2017-05-18
SG11201507574VA (en) 2015-10-29
US20170081382A1 (en) 2017-03-23
SI2970441T1 (en) 2019-07-31
CA3149348C (en) 2023-09-12
NZ712066A (en) 2021-05-28
JP2021040630A (en) 2021-03-18
US9580486B2 (en) 2017-02-28
PT2970441T (en) 2019-06-11
TWI709572B (en) 2020-11-11
CN105143253B (en) 2021-02-19
MA49207B1 (en) 2022-08-31
BR112015023145A2 (en) 2017-11-21
KR20150130342A (en) 2015-11-23
HUE043488T2 (en) 2019-08-28
DK2970441T3 (en) 2019-06-03
AU2014236281B2 (en) 2018-03-08
EA034326B1 (en) 2020-01-28
CR20200004A (en) 2020-03-11
TN2015000416A1 (en) 2017-01-03
UA119140C2 (en) 2019-05-10
EP2970441B1 (en) 2019-03-06
CN105358570A (en) 2016-02-24
MX2015012890A (en) 2015-12-03
BR112015022440B1 (en) 2022-08-16
MA38477A1 (en) 2017-09-29
KR102219124B1 (en) 2021-02-22
ME03437B (en) 2020-01-20
MA49207A1 (en) 2021-09-30
PH12015502051A1 (en) 2016-01-18
TW202115106A (en) 2021-04-16

Similar Documents

Publication Publication Date Title
IL241349B (en) Interleukin-2 muteins for the expansion of t-regulatory cells
IL283764A (en) Interleukin-2 muteins for the expansion of t-regulatory cells
HK1223553A1 (en) Cell
PL2953634T3 (en) Methods for expansion or depletion of t-regulatory cells
HK1219526A1 (en) Expansion anchor
EP2997133C0 (en) Methods for engineering highly active t cell for immunotherapy
HK1219527A1 (en) Expansion anchor
EP2969487A4 (en) Ceramic support structure
IL244345A0 (en) Thermal compressor
GB201421716D0 (en) Cell expansion procedure
HK1221250A1 (en) Structure for culturing cells
EP2975216A4 (en) Cooling promoting structure
IL254966A (en) Interleukin-2 muteins for the expansion of t-regulatory cells
GB201312332D0 (en) Cell locations
GB201310031D0 (en) Cell
ZA201600071B (en) Pyridine-2-carboxamides as nematocides
GB201312803D0 (en) Cell component
TWM432485U (en) Inner expansion jig structure
TWM476588U (en) Waist support structure
GB201303217D0 (en) Bridges Research Application - BRA
GB201320573D0 (en) T Cell
GB201317589D0 (en) Cell
GB201304608D0 (en) BenTime of Yisrael operable arrangement
GB201310963D0 (en) Support structures